Parallel Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $520K | Buy |
9,424
+1,405
| +18% | +$76.1K | 0.01% | 710 |
|
|
2025
Q4 | $393K | Buy |
8,019
+70
| +0.9% | +$3.27K | 0.01% | 778 |
|
|
2025
Q3 | $343K | Sell |
7,949
-1,146
| -13% | -$44.8K | 0.01% | 803 |
|
|
2025
Q2 | $349K | Buy |
9,095
+1,718
| +23% | +$65.6K | 0.01% | 767 |
|
|
2025
Q1 | $286K | Sell |
7,377
-2,463
| -25% | -$90.2K | 0.01% | 803 |
|
|
2024
Q4 | $333K | Buy |
9,840
+1,690
| +21% | +$60.8K | 0.01% | 730 |
|
|
2024
Q3 | $333K | Buy |
8,150
+1,061
| +15% | +$43.4K | 0.01% | 723 |
|
|
2024
Q2 | $273K | Sell |
7,089
-348
| -5% | -$14.6K | 0.01% | 738 |
|
|
2024
Q1 | $319K | Buy |
7,437
+1,207
| +19% | +$49.8K | 0.01% | 685 |
|
|
2023
Q4 | $231K | Sell |
6,230
-954
| -13% | -$34.2K | 0.01% | 739 |
|
|
2023
Q3 | $260K | Buy |
7,184
+793
| +12% | +$28.1K | 0.01% | 673 |
|
|
2023
Q2 | $228K | Buy |
6,391
+1,802
| +39% | +$64.6K | 0.01% | 733 |
|
|
2023
Q1 | $163K | Buy |
4,589
+242
| +6% | +$8.47K | 0.01% | 851 |
|
|
2022
Q4 | $153K | Buy |
4,347
+10
| +0.2% | +$333 | 0.01% | 820 |
|
|
2022
Q3 | $128K | Sell |
4,337
-133
| -3% | -$5.04K | 0.01% | 862 |
|
|
2022
Q2 | $243K | Buy |
4,470
+913
| +26% | +$50.4K | 0.01% | 603 |
|
|
2022
Q1 | $194K | Sell |
3,557
-1,634
| -31% | -$88.8K | 0.01% | 746 |
|
|
2021
Q4 | $286K | Buy |
5,191
+1,105
| +27% | +$57.5K | 0.01% | 612 |
|
|
2021
Q3 | $195K | Buy |
4,086
+531
| +15% | +$26.7K | 0.01% | 729 |
|
|
2021
Q2 | $177K | Buy |
3,555
+989
| +39% | +$47.5K | 0.01% | 727 |
|
|
2021
Q1 | $114K | Sell |
2,566
-552
| -18% | -$25.1K | 0.01% | 832 |
|
|
2020
Q4 | $143K | Buy |
3,118
+632
| +25% | +$29K | 0.01% | 695 |
|
|
2020
Q3 | $117K | Buy |
2,486
+56
| +2% | +$2.81K | 0.01% | 722 |
|
|
2020
Q2 | $123K | Buy |
2,430
+356
| +17% | +$18.3K | 0.01% | 689 |
|
|
2020
Q1 | $98K | Sell |
2,074
-114
| -5% | -$6.08K | 0.01% | 687 |
|
|
2019
Q4 | $129K | Sell |
2,188
-318
| -13% | -$17.7K | 0.01% | 677 |
|
|
2019
Q3 | $134K | Sell |
2,506
-112
| -4% | -$5.76K | 0.01% | 615 |
|
|
2019
Q2 | $131K | Sell |
2,618
-546
| -17% | -$27.4K | 0.01% | 581 |
|
|
2019
Q1 | $165K | Sell |
3,164
-236
| -7% | -$11.8K | 0.02% | 468 |
|
|
2018
Q4 | $162K | Buy |
3,400
+377
| +12% | +$18.6K | 0.02% | 416 |
|
|
2018
Q3 | $152K | Buy |
3,023
+3
| +0.1% | +$152 | 0.02% | 473 |
|
|
2018
Q2 | $152K | Buy |
3,020
+37
| +1% | +$1.86K | 0.02% | 434 |
|
|
2018
Q1 | $146K | Buy |
2,983
+313
| +12% | +$14.6K | 0.02% | 403 |
|
|
2017
Q4 | $118K | Sell |
2,670
-1,116
| -29% | -$51.6K | 0.02% | 440 |
|
|
2017
Q3 | $166K | Buy |
3,786
+548
| +17% | +$27.8K | 0.03% | 356 |
|
|
2017
Q2 | $164K | Buy |
3,238
+1,564
| +93% | +$83.4K | 0.03% | 359 |
|
|
2017
Q1 | $86K | Buy |
1,674
+729
| +77% | +$37K | 0.02% | 492 |
|
|
2016
Q4 | $45K | Buy |
+945
| New | +$46.7K | 0.01% | 620 |
|
Other funds holding GSK
JEST
Parallel Advisors's GSK Position: Q1 2026 in Review
Parallel Advisors increased its GSK (GSK) stake by 18% in Q1 2026, buying an estimated $76.1K and bringing the position to 9,424 shares worth $520K. The position accounts for 0.01% of the portfolio, ranked #710.
Parallel Advisors first reported a position in GSK in Q4 2016 and has held it in 38 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Parallel Advisors held 9,424 shares of GSK worth $520K as of Q1 2026.
- Parallel Advisors bought 1,405 GSK shares in Q1 2026, an estimated $76.1K.
- GSK made up 0.01% of Parallel Advisors's portfolio in Q1 2026, its #710 holding.
- Parallel Advisors first reported a position in GSK in Q4 2016 and has held it in 38 quarters since.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.